Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongfeng Kangning Pian is a traditional Chinese medicine (TCM) tablet formulation developed by Tianjin Tianzhong Pharmaceutical Technology for the treatment of acute gouty arthritis. It is specifically indicated for patients presenting with the TCM pattern of damp-heat and blood stasis. The drug is currently being evaluated in Phase 2 clinical trials in China to determine its efficacy, safety, and optimal dosage. As a botanical-based therapy, it is designed to alleviate the pain and inflammation associated with gout flares by addressing the underlying damp-heat and blood stasis syndromes characteristic of the condition in TCM theory.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongfeng Kangning Pian.